Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)